Compare · APGE vs BIIB
APGE vs BIIB
Side-by-side comparison of Apogee Therapeutics Inc. (APGE) and Biogen Inc. (BIIB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both APGE and BIIB operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BIIB is the larger of the two at $30.41B, about 3.0x APGE ($10.10B).
- Over the past year, APGE is up 240.9% and BIIB is up 64.8% - APGE leads by 176.1 points.
- APGE has been more active in the news (18 items in the past 4 weeks vs 16 for BIIB).
- BIIB has more recent analyst coverage (25 ratings vs 19 for APGE).
- Company
- Apogee Therapeutics Inc.
- Biogen Inc.
- Price
- $134.00-0.05%
- $206.02-1.49%
- Market cap
- $10.10B
- $30.41B
- 1M return
- +57.30%
- +5.35%
- 1Y return
- +240.88%
- +64.80%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2023
- News (4w)
- 18
- 16
- Recent ratings
- 19
- 25
Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; Capsigen Inc.; and Mirimus, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Latest APGE
- Chief Medical Officer Dambkowski Carl gifted 8,000 shares, decreasing direct ownership by 4% to 169,873 units (SEC Form 4)
- SEC Form DEFM14A filed by Apogee Therapeutics Inc.
- Chief Executive Officer Henderson Michael Thomas sold $2,672,600 worth of shares (20,000 units at $133.63) as part of a pre-agreed trading plan and gifted 75,046 shares, decreasing direct ownership by 9% to 920,941 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Apogee Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Apogee Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Apogee Therapeutics Inc.
- Chief Medical Officer Dambkowski Carl sold $730,070 worth of shares (5,500 units at $132.74) as part of a pre-agreed trading plan and exercised 4,125 shares at a strike of $22.86, decreasing direct ownership by 0.77% to 177,873 units (SEC Form 4)
- SEC Form PREM14A filed by Apogee Therapeutics Inc.
- SEC Form DEFA14A filed by Apogee Therapeutics Inc.
- Chief Medical Officer Dambkowski Carl sold $3,500,640 worth of shares (26,400 units at $132.60) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 179,248 units (SEC Form 4)
Latest BIIB
- Synapticure Launches Groundbreaking Ataxia Care Program, Expanding Access to Specialized Neurology Nationwide
- Biogen Appoints Michael J. Parini as Chief Legal Officer
- LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer’s Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
- LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
- Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease
- FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease
- FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease
- Biogen upgraded by Truist with a new price target
- Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer
- LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer’s Disease Presented at the Alzheimer’s Association International Conference® (AAIC®) 2026